je.st
news
Tag: therapies
NIH Scientists Pursue New Therapies To Improve Rare Disease Drug Development
2013-10-02 06:18:51| drugdiscoveryonline News Articles
Four new pre-clinical drug development projects at the National Institutes of Health will target a form of blindness and diseases characterized by cardiac problems. The projects were selected for their potential to treat specific rare diseases and to help scientists uncover new information that can be shared with other researchers
Tags: development
improve
drug
disease
Vital Therapies, Inc. Expands Executive Team
2013-09-06 17:26:10| Biotech - Topix.net
Michael Swanson has joined VTI as Chief Financial Officer and Treasurer, bringing more than 20 years of experience in senior financial positions in public and private life sciences companies.
Tags: team
executive
vital
expands
MSD Statement Regarding CHMP Review of Incretin-Based Therapies for Type 2 Diabetes, Including Sitagliptin
2013-07-26 16:16:00| Merck.com - Product News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck Sharpe and Dohme (MSD), known as Merck in the United States and Canada, issued the following statement regarding the conclusion of the European Medicines Agencys (EMA) Committee for Medicinal Products for Human Use (CHMP) review of GLP-1, or incretin-based, therapies, including sitagliptin. Language: English Contact: MSDMedia:Pam Eisele, +1-908-423-5042Michael Close, +1-267-305-1211Investor:Carol Ferguson, +1-908-423-4465 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: type
including
review
statement
Merck Statement Regarding CHMP Review of Incretin-Based Therapies for Type 2 Diabetes, Including Sitagliptin
2013-07-26 15:15:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck, known as MSD outside the United States and Canada, issued the following statement regarding the conclusion of the European Medicines Agencys (EMA) Committee for Medicinal Products for Human Use (CHMP) review of GLP-1, or incretin-based, therapies, including sitagliptin. Language: English Contact: MerckMedia:Pam Eisele, 908-423-5042Mary Elizabeth Blake, 908-423-5550orInvestors:Carol Ferguson, 908-423-4465 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: type
including
review
statement
U.S. drugmakers cheer 'speed lane' for breakthrough therapies
2013-07-25 07:40:41| Biotech - Topix.net
A new regulatory pathway could shave years off the traditional drug approval process in the United States, according to some companies whose drugs have been given "breakthrough therapy" designation by the U.S. Food and Drug Administration.
Tags: speed
lane
breakthrough
cheer